FTRE — Fortrea Holdings Inc.

Summary of FTRE Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $701.3 million, up 3.9% year-over-year.
• Adjusted EBITDA: $50.7 million, down from $64.2 million in the prior year, primarily due to project mix and increased pass-through costs.
• Net Loss: $15.9 million, an improvement from a loss of $18.5 million in Q3 2024.
• Adjusted Net Income: $11.7 million, down from $20.7 million year-over-year.
• Book-to-Bill Ratio: 1.13x for the quarter; trailing 12-month ratio at 1.07x.
• Backlog: Over $7.6 billion.
• Cash Flow: Positive operating cash flow of $87 million and free cash flow of $80 million for the quarter.

2. Strategic Updates and Business Highlights

• Leadership Transition: Anshul Thakral marked his first 100 days as CEO, focusing on client engagement and operational excellence.
• Client Wins: Significant awards from both new and repeat clients, particularly in clinical pharmacology and full-service clinical development.
• Operational Improvements: Enhanced Net Promoter Scores and reduced time to site selection by 33%.
• Technology Initiatives: Continued investment in AI and technology to improve operational efficiency, including the launch of new digital tools.
• Cost Optimization: Progress toward $150 million in gross savings, with over $95 million captured year-to-date.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased to $2.7 billion - $2.75 billion for FY 2025.
• Adjusted EBITDA Guidance: Narrowed to $175 million - $195 million.
• Cash Flow Outlook: Targeting slightly negative operating cash flow for the full year, with expectations of positive cash flow in Q4 2025.

4. Challenges and Points of Concern

• Margin Pressure: Adjusted EBITDA decline attributed to a higher proportion of pass-through costs and the reintroduction of variable compensation.
• Cancellation Rate: Slight increase in cancellations, though still within historical ranges.
• Competitive Pricing Environment: Ongoing competitive pressures in the FSP segment, with some larger CROs adopting aggressive pricing strategies.
• Dependence on Top Clients: Top 10 customers accounted for 60% of revenues, with the largest client representing nearly 20%.

5. Notable Q&A Insights

• Client Engagement: The company is focusing on improving account management and client relationships, especially with biotech clients, leading to a significant increase in RFP volumes and win rates.
• Decision-Making Trends: Positive trends observed in decision-making timelines for biotech clients, with some projects moving forward more quickly than previously anticipated.
• FSP Sales Team: Early traction noted, but longer sales cycles expected due to the nature of FSP contracts.
• Pricing Strategy: The CEO emphasized the importance of maintaining pricing discipline while navigating a competitive environment, with a focus on holding prices when possible.

Overall, Fortrea demonstrated solid financial performance in Q3 2025, with strategic initiatives aimed at improving client engagement and operational efficiency. However, challenges remain in terms of margin pressures and competitive dynamics within the CRO industry.